The honest answer to whether it regrows cartilage

The short answer is: not exactly — and understanding why that matters is more useful than a yes or a no.

ChondroFiller® does not inject ready-made cartilage cells or pre-formed tissue into the joint. What it delivers is a collagen scaffold that, once placed under ultrasound guidance, gels in situ and creates the conditions for the body's own progenitor cells to migrate in, differentiate, and begin producing repair matrix. The clinical term for this is acellular matrix-induced chondrogenesis — the device contains no live cells, no growth factors, and no pharmacological agents. The biology is the patient's own.

Whether that repair tissue is true hyaline cartilage or the mechanically inferior fibrocartilage has not yet been confirmed by human histological studies. Published evidence is functional and imaging-based — MRI MOCART scores and patient-reported outcomes — rather than biopsy-proven at the tissue level. That gap is real, and it is worth holding in mind alongside the clinical results that follow.

What the evidence does support is that ChondroFiller promotes endogenous repair rather than substituting for it.

Why cartilage cannot repair itself without help

Articular cartilage has no blood supply and no nerve fibres running through it. That absence of vasculature is what makes cartilage damage so persistent: there are no blood vessels to ferry repair signals to the injury site, and no vascular pathway along which progenitor cells can travel to begin rebuilding damaged tissue. A cut in skin bleeds, clots, and heals because the circulatory system reaches it. A focal cartilage defect cannot trigger that cascade — it simply remains.

The joint environment compounds the problem. Synovial fluid circulates continuously through the joint cavity, and that constant turnover means any cells attempting to settle in the void of a defect are washed away within hours. The same mechanism defeats freely injected biologics: without a physical anchor at the lesion site, even a concentrate rich in mesenchymal stem cells disperses into the joint before it can do useful work.

This is the specific problem ChondroFiller is designed to address — not by supplying repair cells itself, but by providing the structural matrix that holds the environment still long enough for the patient's own biology to act.

How the collagen scaffold gels and recruits cells

The two-component design is what makes in-situ gelation possible. Delivered through a needle under ultrasound guidance, the precursor components meet and cross-link at the tip, converting from liquid to a porous three-dimensional hydrogel within minutes of placement. No shaping is required: the gel flows into the irregular contours of the defect and sets there, transforming what was an open, fluid-swept void into a stable, cell-retaining matrix.

That structural stability is the first step; the scaffold's porosity drives the second. The interconnected pore network acts as a chemotactic framework — a three-dimensional lattice that signals to mesenchymal stem cells and progenitor cells in the surrounding subchondral bone and synovium, drawing them inward. Once recruited, those cells populate the matrix, receive cues from the collagen environment, differentiate into chondrocyte-like cells, and begin depositing extracellular repair matrix. As new tissue matures and consolidates, the temporary collagen scaffold is gradually resorbed and replaced by what the body has built inside it.

When ChondroFiller is combined with BMAC — a concentrate of mesenchymal stem cells derived from the patient's own bone marrow — this anchoring property becomes doubly important. BMAC carries a high cellular payload, but that payload needs a physical home at the lesion site to be useful. Co-delivered into the setting gel, the MSC-rich concentrate is held within the scaffold rather than carried away by circulating synovial fluid. ChondroFiller provides the structural anchor; BMAC provides the cellular resource. The two work through distinct mechanisms and should not be thought of as interchangeable.

What the experimental evidence shows about cell recruitment

The clearest mechanistic confirmation comes from a 2025 ex vivo osteochondral study using 61 cartilage explants with 4 mm full-thickness defects. ChondroFiller-treated specimens showed a 2.4-fold increase in DNA content by day 14 — a direct measure of cells entering the scaffold. DNA content is a proxy for cell number, so this figure is not a theoretical extrapolation: it is a count of biological material that was not there before treatment and is now inside the matrix.

Explants additionally treated with mesenchymal stem cells produced measurably greater collagen and glycosaminoglycan (GAG) deposition. Crucially, the study found significant correlations between DNA and collagen content specifically in scaffold-treated specimens — linking the number of cells recruited to the volume of repair matrix those cells produced. That correlation is what converts a recruitment observation into a functional finding.

Ex vivo models cannot replicate the full complexity of a living joint, so these results confirm that the recruitment mechanism works under controlled conditions rather than establishing final clinical outcomes. The same distinction applies to real-world exposure data: over 19,000 ChondroFiller treatments have now been performed globally, a figure that provides a broad safety and tolerability signal across diverse clinical settings. It is observational in nature, not a matched-control dataset, and does not on its own prove the degree or durability of cartilage regeneration achieved.

Clinical outcomes: what patients typically report

Functional improvements in published knee studies are both consistent and, by clinical standards, substantial. The IKDC score — a 0–100 scale where higher values indicate better function and less pain — improved by approximately 30 points across four published knee studies, more than double the 16.7-point threshold that defines a meaningful change for patients. In practical terms, a gain of that magnitude typically corresponds to moving from significant difficulty with daily activities such as stairs or uneven ground towards a capacity for recreational sport and sustained walking without constant discomfort.

The Jerosch post-market clinical follow-up study recorded a 32.4-point IKDC improvement sustained at three years, with a final functional score of 80 — suggesting that rebuilt tissue does not simply hold position at twelve months and then decline.

MRI provides an independent line of evidence. MOCART scores — which quantify defect filling and tissue integration on imaging — reached 81.6 to 84.3 in European knee studies, indicating more than 80% defect filling and good border integration with surrounding native cartilage. The trajectory is as informative as the endpoint: scores of 65.3 at four weeks rose to 81.6 at one year, confirming that repair is a progressive process rather than an immediate structural event. Patients should expect gradual improvement across the first twelve months, not a recovery that is complete at the six-week mark.

A 2024 knee series of 17 patients with a mean age of 31 years, and a 2025 wrist study of 25 patients, extend these findings to younger patients and smaller joints, with statistically significant outcome score improvements recorded at three, six, and twelve months. These are observational and PMCF datasets rather than large randomised controlled trials, and outcomes will vary with defect size, joint location, and patient selection.

Who is likely to benefit — and known limitations of the evidence

The clearest contraindication running across multiple studies is also the most clinically actionable: patients with pre-existing Tönnis grade 2–3 osteoarthritis had uniformly poor outcomes in the hip cohort and other published series. A focal scaffold relies on a contained defect with healthy surrounding cartilage to anchor against; widespread joint degeneration removes that architectural prerequisite. This is not an edge case — it is the dominant reason suitability assessment matters more than any individual outcome figure.

A 2024 biomechanical in vitro study found the gel does not reduce damage to opposing cartilage under full cyclic loading, attributing this to the early mechanical instability of a setting hydrogel. That finding is not a failure of design — it is the biomechanical rationale for the six-week protected weight-bearing protocol. The scaffold needs time to mature before load transfer is appropriate, and the protocol reflects that.

Two evidence gaps are worth naming honestly. The 2016 randomised controlled trial against microfracture was underpowered by high dropout in the comparator arm, leaving head-to-head data limited. And beyond three to five years, randomised outcome data and histological confirmation of true hyaline — rather than fibrocartilage — regeneration in living patients do not yet exist in the published record. What does exist is a consistent functional signal across joint types and patient ages, alongside progressive MRI maturation at one year.

Determining whether this pathway is appropriate requires MRI characterisation of defect size, location, containment, and background OA grade — questions that a dedicated cartilage assessment is designed to answer before any treatment decision is made.

1. [1] IMPLANTATION OF CHONDROFILLER LIQUID® AS A SCAFFOLD MATERIAL FOR THE TREATMENT OF CHONDRAL LESIONS OF THE KNEE JOINT. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
3. [3] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z